Celldex Therapeutics, Inc.
CLDX
$15.94
-$0.47-2.86%
| Weiss Ratings | CLDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | CLDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | CLDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.80 | |||
| Price History | CLDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -5.40% | |||
| 30-Day Total Return | -21.52% | |||
| 60-Day Total Return | -30.51% | |||
| 90-Day Total Return | -42.85% | |||
| Year to Date Total Return | -38.19% | |||
| 1-Year Total Return | -59.33% | |||
| 2-Year Total Return | -49.40% | |||
| 3-Year Total Return | -53.36% | |||
| 5-Year Total Return | 761.62% | |||
| 52-Week High % Change | -65.09% | |||
| 52-Week Low % Change | 13.96% | |||
| Price | CLDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $47.00 | |||
| 52-Week Low Price | $14.40 | |||
| 52-Week Low Price (Date) | Apr 09, 2025 | |||
| 52-Week High Price (Date) | Sep 25, 2024 | |||
| Valuation | CLDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 1.09B | |||
| Enterprise Value | 367.89M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -2.45 | |||
| Earnings Per Share Growth | -16.08% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 155.25 | |||
| Price/Book (Q) | 1.46 | |||
| Enterprise Value/Revenue (TTM) | 52.41 | |||
| Price | $15.94 | |||
| Enterprise Value/EBITDA (TTM) | -1.92 | |||
| Enterprise Value/EBIT | -1.89 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | CLDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 66.35M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | CLDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 908 200 7500 | |||
| Address | Perryville III Building Hampton, NJ 08827 | |||
| Website | www.celldex.com | |||
| Country | United States | |||
| Year Founded | -- | |||
| Profitability | CLDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -2,778.88% | |||
| Profit Margin | -2,248.76% | |||
| Management Effectiveness | CLDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -19.38% | |||
| Return on Equity | -- | |||
| Income Statement | CLDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 7.02M | |||
| Total Revenue (TTM) | 7.02M | |||
| Revenue Per Share | $0.11 | |||
| Gross Profit (TTM) | -120.73M | |||
| EBITDA (TTM) | -191.90M | |||
| EBIT (TTM) | -195.08M | |||
| Net Income (TTM) | -157.86M | |||
| Net Income Avl. to Common (TTM) | -157.86M | |||
| Total Revenue Growth (Q YOY) | -71.56% | |||
| Earnings Growth (Q YOY) | -8.74% | |||
| EPS Diluted (TTM) | -2.45 | |||
| EPS Diluted Growth (Q YOY) | 14.74% | |||
| Balance Sheet | CLDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 725.28M | |||
| Cash Per Share (Q) | $10.93 | |||
| Total Current Assets (Q) | 747.16M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 747.01M | |||
| Current Ratio (Q) | 18.915 | |||
| Book Value Per Share (Q) | $11.25 | |||
| Total Assets (Q) | 792.34M | |||
| Total Current Liabilities (Q) | 39.50M | |||
| Total Debt (Q) | 3.81M | |||
| Total Liabilities (Q) | 45.34M | |||
| Total Common Equity (Q) | 747.01M | |||
| Cash Flow | CLDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -290.13M | |||
| Cash from Financing (TTM) | 441.45M | |||
| Net Change in Cash (TTM) | -6.46M | |||
| Levered Free Cash Flow (TTM) | -91.67M | |||
| Cash from Operations (TTM) | -157.78M | |||
